Advancing Breast Cancer Treatment: A Comprehensive Exploration of CDK4/6 Inhibitors

Advancing Breast Cancer Treatment: A Comprehensive Exploration of CDK4/6 Inhibitors

This session, moderated by Prof. Cortes and presented by Prof. Barrios and Prof. Del Mastro, focused on the mechanisms of action and clinical implications of CDK 4/6 inhibitors in hormone receptor-positive breast cancer.

Prof. Carlos Barrios focused on the mechanisms of action, clinical implications, and comparative effectiveness of CDK 4/6 inhibitors in treating hormone receptor-positive breast cancer.

1:22 - Mechanism of Action of CDK 4/6 Inhibitors: Prof. Barrios discusses the complex biology of hormone receptor-positive breast cancer and the role of CDK 4/6 inhibitors.

3:41 - Cell Cycle and Estrogen Signaling: He explains the interaction between estrogen signaling and the cell cycle, emphasizing the importance of cyclin D and CDK 4/6.

8:18 - Clinical Implications and Differences Among CDK 4/6 Inhibitors: He compares the three CDK 4/6 inhibitors (Palbociclib, Ribociclib, Abemaciclib) and their clinical effects.

12:21 - Clinical Trials and Results: He reviews the outcomes of various clinical trials involving CDK 4/6 inhibitors in early breast cancer.

14:23 - Future Perspectives: He discusses the future development of combination therapies and the need for smarter trials to address sequencing strategies.

Prof. Lucia Del Mastro discussed the use of CDK 4/6 inhibitors, specifically abemaciclib and ribociclib, in early breast cancer treatment, highlighting their clinical benefits, differences in toxicity profiles, and guidelines for their use.

0:31 - Summary of CDK 4/6 Inhibitors: Lucia summarized the current role and open questions on the use of CDK 4/6 inhibitors in early breast cancer patients.

1:31 - Registration Trials: Overview of the registration trials for abemaciclib (MONARCHY trial) and ribociclib (Natalee trial), including their benefits in invasive disease-free survival.

7:18 - ESMO and ASCO Guidelines: Comparison of ESMO and ASCO guidelines on the use of CDK 4/6 inhibitors in early breast cancer patients.

9:12 - Risk Assessment: Analysis of patient outcomes based on risk criteria from the MONARCHY and Natalee trials.

11:00 - Conclusion: Final remarks on the benefits and considerations for using CDK 4/6 inhibitors in early breast cancer patients.

Panel Discussion

0:12 - Comparison of Three Drugs in Breast Cancer Treatment: Discussed the similarities and differences in progression-free survival and long-term outcomes of Palbociclib, Ribociclib, and Abemaciclib in metastatic and early breast cancer settings.

1:11 - Efficacy and Superiority of Abemaciclib and Ribociclib: Analysis of network meta-analysis and real-world studies showing the superiority of Abemaciclib and Ribociclib in breast cancer treatment.

2:23 - Patient Selection for CDK4/6 Inhibitors: Discussion on selecting the right patient population for CDK4/6 inhibitors and the impact of trial design on drug development.

3:28 - Inclusion Criteria for Monarch E and Natalee Trials: Analysis of the inclusion criteria for these trials and considerations for high-risk patients not included in the studies.

6:07 - Combination Therapies with CDK4/6 Inhibitors: Discussion on the potential of combining CDK4/6 inhibitors with AKT pathway inhibitors and the effectiveness of sequential treatments.

10:02 - Practical Considerations for Dose Adjustments: Addressing dose adjustments for Abemaciclib and Ribociclib in cases of significant side effects and the possibility of switching between these drugs.

13:00 - Re-challenging with CDK4/6 Inhibitors: Considerations for re-challenging patients with CDK4/6 inhibitors after disease progression and the potential benefits of switching between these inhibitors.

This site is only for use by healthcare professionals.

By continuing to view this site you are confirming that you are a healthcare professional.

Confirm